AstraZeneca reports promising results from lung cancer drug trials

AstraZeneca photo

AstraZeneca has reported promising results from trials for lung cancer drugs.

Showing promise was a late-stage trial of its cancer drug Tragrisso.

The Phase III Flaura trial was used which was used in the treatment of forms of non-small cell lung cancer.

Results of the Phase III Flaura trial were included at the Presidential Symposium I of the European Society of Medical Oncology 2017 Congress in Madrid, Spain.


Sean Bohen, executive vice president, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The Flaura data suggest early and sustained benefit withTagrissothat has the potential to significantly impact long-term patient outcomes and help address the considerable unmet need that remains.”

AstraZeneca and MedImmune, its global biologics research and development arm, also presented data from a planned interim analysis of the Phase III Pacific trial for a type of non-small cell lung cancer.

Results of the Pacific trial were also included at the Presidential Symposium I.

Bohen, stated: “The Phase III Pacific results are incredibly encouraging for a patient population that until now has been without treatment options.”

The Endpoints website and newsletter reported the two trials were good news for a company that has seen its share of setbacks in working to bolster its drug pipeline.

Facebook Comments
Previous articleIncyte poised to sell more than $700 million in stock
Next articleState seeks civil penalties in connection with pawn shop bust
Delaware Business Now is a four-year-old, five-day-a-week newsletter and website operated by Bird Street Media LLC. Publisher and Chief Content Officer is Doug Rainey, a 30-year veteran of business journalism in the state of Delaware.  Business Now focuses on breaking business news in Delaware and immediate adjacent areas with apropriate background and perspective. Also offered exclusively in our FREE newsletter is commentary on state and regional issues. Have a complaint, question or even a compliment? Send an email to For advertising information, click on the About tab at the top of the home page Our business hours are 8 a.m. to 5 p.m., Monday through Friday. Call us at 302.753.0691.